Catalyst Pharma appoints Dr. William Andrews as CMO; Dr. Ingenito retires

CATALYST PHARMACEUTICALS, INC.

Gary Ingenito retired as Chief Medical and Regulatory Officer effective June 1, 2025; no disagreement with management.
William Andrews appointed as new Chief Medical Officer effective June 2, 2025, reporting to CEO Richard Daly.
Andrews brings 24 years of biopharma experience, including CMO roles at Flexion, Akcea, and Acer Therapeutics.
Ingenito will serve as a consultant to assist with the transition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.